Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

22 results about "Renal vessels" patented technology

The renal artery is one of two blood vessels that leads off from the abdominal aorta to the kidney. The other blood vessel is the renal vein.

Method for determining the correct position of windows in relation to the visceral and renal vessels in aortic endoprostheses

PCT designated stageWO2026105045A1StentsImage enhancementAorta aorticAorta diameter
Method for determining the position of windows in aortic endoprostheses, using images from preoperative CT computed tomography, wherein such endoprosthesis comprises a tubular sleeve (1) having a diameter slightly greater than the diameter of such aorta, on which one or more windows (2) must be made in correspondence with the centre of origin of a blood vessel branching from such aorta. The method comprises the following steps: a) on the axial image of such tomography, calculating the aortic arc of circle (AA) between the position (PB) of such centre of origin of the vessel with respect to a reference point (OA) taken on the circumference of the aorta, b) calculating a conversion parameter (P) dependent on the difference between the diameter of the aortic artery and that of the tubular sleeve (1), c) determining the position of the window (PF) on the prosthesis by calculating the arc of circle on the prosthesis (AM) between a reference point (OM) taken on the tubular sleeve (1), placed in juxtaposition to such reference point (OA) on the aorta (A), and such position (PF), by subtracting the value of such conversion parameter (P) from the value of the aortic arc of circle (AA).
Owner:UNIV DEGLI STUDI DI PADOVA

Monitoring of neuromodulation using biomarkers

Provided herein are methods, devices, compositions, and kits for monitoring neuromodulation efficacy based on changes in the level or activity of one or more target biomarkers. A method can include transluminally delivering a distal portion of an elongated shaft of a catheter to a target renal blood vessel and at least partially inhibiting sympathetic neural activity of a renal nerve. The method includes determining a post-neuromodulation level of one or more biomarkers after at least partially inhibiting the sympathetic neural activity of the renal nerve, wherein the level of the one or more biomarkers directly or indirectly correlates with sympathetic nervous activity in the patient. The method can include comparing the post-neuromodulation level to a predetermined level for the one or more biomarkers, wherein the renal neuromodulation procedure is classified as at least partially successful if the post-neuromodulation level differs from the predetermined level.
Owner:MEDTRONIC IRELAND MFG UNLIMITED CO

Renovascular treatment device, system, and method for radiosurgically alleviating hypertension

A radiosurgical method for treating cardiorenal disease of a patient, the method including directing radiosurgery radiation from outside the patient towards one or more target treatment regions encompassing sympathetic ganglia of the patient so as to inhibit the cardiorenal disease. In an exemplary embodiment, the method further includes acquiring three dimensional planning image data encompassing the first and second renal arteries, planning an ionizing radiation treatment of first and second target regions using the three dimensional planning image data so as to mitigate the hypertension, the first and second target regions encompassing neural tissue of or proximate to the first and second renal arteries, respectively, and remodeling the target regions by directing the planned radiation from outside the body toward the target regions.
Owner:VARIAN MEDICAL SYSTEMS INC

Active low molecular weight variants of angiotensin converting enzyme 2 (ACE2)

InactiveUS20240392274A1Powder deliveryAntibody mimetics/scaffoldsCardiac fibrosisAtherosclerosis renal artery
Disclosed are variants of ACE2, pharmaceutical compositions comprising the variants of ACE2, and treatment methods for reducing Angiotensin II(1-8) plasma levels and / or increasing Angiotensin (1-7) plasma levels in a subject in need thereof. The disclosed variants of ACE2 may include polypeptide fragments of ACE2 having ACE2 activity for converting AngII(1-8) to Ang(1-7). Suitable subjects suitable for the disclosed methods of treatment may include subjects having or at risk for developing diabetic and non-diabetic chronic kidney disease, acute renal failure and its prevention, chronic kidney disease, severe hypertension, scleroderma and its skin, pulmonary, kidney and hypertensive complications, malignant hypertension, renovascular hypertension secondary to renal artery stenosis, idiopathic pulmonary fibrosis, liver fibrosis such as in liver cirrhosis patients, an aortic aneurysm, cardiac fibrosis and remodeling, left ventricular hypertrophy, and an acute stroke.
Owner:NORTHWESTERN UNIV

Method for Evaluating Outcome of Renal Denervation

A method for evaluating an outcome of renal denervation includes: acquiring first blood flow data from a first region in a renal blood vessel after a vasodilator injected into the first region is activated in a second region in the renal blood vessel; and acquiring second blood flow data from the first region after renal denervation is performed with a catheter for denervation.
Owner:PARK EUL JOON

Renal vasoconstriction and renal blood flow response to stimulation as a guide to renal denervation

PCT designated stageWO2025176672A1Ultrasound therapyElectrotherapyVascular constrictionTherapeutic Devices
A method of performing a therapeutic procedure includes navigating a therapeutic device to a location adjacent to target tissue, determining a first flow parameter within a blood vessel adjacent to the target tissue, applying neurostimulation to the target tissue and obtaining first images of blood vessels distal of the target tissue, applying therapy to the target tissue, applying neurostimulation to the target tissue, determining a second flow parameter within the blood vessel adjacent to the target tissue, comparing the second flow parameter to a flow parameter criteria, applying neurostimulation to the target tissue and obtaining second images of the blood vessels distal of the target tissue, comparing the first images to the second images to determine a vasoconstriction metric, and applying therapy to the target tissue if it is determined that the vasoconstriction metric satisfies a vasoconstriction criteria.
Owner:MEDTRONIC IRELAND MFG UNLIMITED CO

A method for dynamic cardiac ultrasound simulation based on statistical ray tracing

The present invention discloses a cardiac dynamic ultrasound simulation method based on statistical ray tracing, which belongs to the cross-technical field of computer graphics and medical simulation, and comprises S1: initializing world parameters of a physical simulation computing engine, and defining human tissue material information according to the physical properties of the heart, liver, kidney, blood vessel, lung, etc.; S2: defining scene file parameters and initializing the scene; S3: calculating the relative position and rotation of each joint in the cardiac model through the transformation matrix, obtaining each frame of grid information through the transformation matrix and importing it into the physical simulation computing engine, and updating the grid according to the time cycle; S4: the ultrasonic probe emits rays according to the sampling angle to perform statistical ray tracing; S5: generating an ultrasonic image through echoes; the present invention takes into account the scattering, absorption and propagation of sound waves in tissues, helps to simulate the formation of ultrasonic images, improves the physical accuracy of the simulation results, and realizes real-time simulation imaging of tissue and organ movement.
Owner:SOUTHWEST PETROLEUM UNIV

Systems, devices, and methods for assessing efficacy of renal neuromodulation therapy

Systems and methods for performing, assessing, and adjusting neuromodulation therapy are disclosed herein. One method for assessing the likely efficacy of neuromodulation therapy includes positioning a neuromodulation catheter at a target site within a renal blood vessel of a human patient and obtaining a measurement related to a diameter of the renal blood vessel via the neuromodulation catheter. The method can further include determining a diameter of the renal blood vessel at or near the target site based on the measurement. In some embodiments, (i) one or more parameters of neuromodulation energy to be delivered to the renal blood vessel can be adjusted based on the determined diameter and / or (ii) the neuromodulation catheter may be repositioned within the renal blood vessel.
Owner:MEDTRONIC IRELAND MFG UNLIMITED CO

Application of 18F-FAPI-42 in preparation of product for diagnosing lung lymphangioleiomyomatosis

The invention relates to application of 18F-FAPI-42 in preparation of a product for diagnosing lung lymphangioleiomyomatosis, and belongs to the technical field of radiography imaging agents. The invention discloses an application of < 18 > F-FAPI-42 in preparation of a product for diagnosing lung lymphangioleiomyomatosis. FAPI is a novel PET tracer agent, PET / CT of FAPI has the advantages of being low in radiation exposure, fast in-vivo metabolism and free of influences of blood glucose level changes, and patient tolerance is better. Compared with 68Ga, the radioactive isotope 18F has a longer half-life period and higher electron energy, and has more advantages in clinical use. As a novel PET / CT tracer, the 18F-FAPI-42 is remarkably superior to a traditional tracer 18F-FDG in the aspects of evaluating the condition of an LAM patient and identifying the focus of the LAM patient, including renal vascular smooth muscle lipoma, mediastinal lymphatic vessel myoma, abdominal lymphatic vessel myoma and pelvic lymphatic vessel myoma.
Owner:THE FIRST AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIV (GUANGZHOU RESPIRATORY CENT)

Systems, devices and methods for evaluating the efficacy of renal neuromodulation therapy

Disclosed herein are systems and methods for performing, evaluating, and adjusting neuromodulation therapy. A method for evaluating the possible efficacy of a neuromodulation therapy includes positioning a neuromodulation catheter at a target site within a renal vessel of a human patient, and obtaining measurements related to a diameter of the renal vessel via the neuromodulation catheter. The method may further include determining a diameter of the renal vessel at or near the target site based on the measurements. In some embodiments, (i) one or more parameters of the neuromodulation energy to be delivered to the renal vessel may be adjusted based on the determined diameter and / or (ii) the neuromodulation catheter may be repositioned within the renal vessel.
Owner:MEDTRONIC ARDIAN LUXEMBOURG SARL

Method for evaluating outcome of renal denervation

According to an embodiment disclosed herein, a method for evaluating the outcome of renal denervation comprises the steps of: acquiring first blood flow data from a first region in a renal blood vessel after a vasodilator injected into the first region is activated in a second region in the renal blood vessel; and acquiring second blood flow data from the first region after renal denervation is performed with a catheter for denervation. In addition, according to an embodiment disclosed herein, a device for evaluating the outcome of renal denervation comprises: a first input unit for inputting first blood flow data acquired from a first region in a renal blood vessel after a vasodilator injected into the first region is activated in a second region; and a second input unit for inputting second blood flow data acquired from the first region after renal denervation is performed with a catheter.
Owner:PARK EUL JOON

A method for constructing a kidney humanized mouse model

The present application belongs to the field of biomedical technology, and relates to a construction method of an experimental animal model and a constructed experimental model, in particular to a method for constructing a kidney humanized mouse model based on human cells and a constructed kidney humanized mouse model. The construction method comprises the following steps: injecting mesenchymal stem cells, human umbilical vein endothelial cells and human renal tubular epithelial cells separated from urine into immunodeficient mice subcutaneously or subcapsularly to obtain a humanized kidney vascular unit mouse model communicating with the host. The model construction has the following characteristics: the cells used are derived from urine, have the characteristics of sufficient clinical source and convenient sampling, and the kidney source cells derived from urine can represent a unique individual alone, can be used to establish an individualized kidney humanized mouse model based on patients, and have the potential to be applied to individualized precision medical research; the model can form a functional human kidney vascular unit in mice, and has great application prospects in individualized precision medical treatment of kidney disease and human kidney specific virus infection research.
Owner:SHANGHAI PUBLIC HEALTH CLINICAL CENT

Application of cinobufotalin in preparing a drug for treating tuberous sclerosis complex-related renal angiomyolipoma

The present invention belongs to the field of biomedical technologies, and particularly relates to the application of cinobufotalin in the preparation of drugs for treating tuberous sclerosis complex-related renal angiomyolipoma. The cinobufotalin can directly inhibit the growth of tuberous sclerosis complex-related renal angiomyolipoma cells and increase the protein expression level of apoptosis markers in tuberous sclerosis complex-related renal angiomyolipoma cells. The cinobufotalin can be used to prepare drugs for treating tuberous sclerosis complex-related renal angiomyolipoma. At the same time, the cost of cinobufotalin is relatively low, providing a new effective and low-cost potential drug for the treatment of tuberous sclerosis complex-related renal angiomyolipoma.
Owner:EXPERIMENTAL RES CENT CHINA ACAD OF CHINESE MEDICAL SCI +1

Systems and methods for assessing efficacy of renal neuromodulation therapy

Systems and methods for performing and assessing neuromodulation therapy are disclosed herein. One method for assessing the efficacy of neuromodulation therapy includes positioning a neuromodulation catheter at a target site within a renal blood vessel of a human patient and delivering neuromodulation energy at the target site with the neuromodulation catheter. The method can further include obtaining a measurement related to a blood flow rate through the renal blood vessel via the neuromodulation catheter. The measurement can be compared to a baseline measurement related to the blood flow rate through the renal blood vessel to assess the efficacy of the neuromodulation therapy. In some embodiments, the baseline and post-neuromodulation measurements are obtained by injecting an indicator fluid into the renal blood vessel upstream of the target site and detecting a transient change in vessel impedance caused by the indicator fluid.
Owner:MEDTRONIC IRELAND MFG UNLIMITED CO

Application of AS-605240 in treatment of renal vascular smooth muscle lipoma related to nodular sclerosis

The invention provides application of AS-605240 in treatment of renal vascular smooth muscle lipoma related to nodular sclerosis, and belongs to the technical field of biological medicine. According to the application disclosed by the invention, the AS-605240 can be used for directly inhibiting the cell growth of the renal vascular smooth muscle lipoma related to the nodular sclerosis, and the AS-605240 can be used for preparing a medicine for resisting the renal vascular smooth muscle lipoma related to the nodular sclerosis, so that a new potential medicine is provided for treating the renal vascular smooth muscle lipoma related to the nodular sclerosis. The invention proves that AS-605240 can promote apoptosis of renal vascular smooth muscle lipoma cells related to the nodular sclerosis through a non-mTOR target point PI3K / AKT, so that the AS-605240 can treat the renal vascular smooth muscle lipoma related to the nodular sclerosis, and has good treatment and improvement effects on the renal vascular smooth muscle lipoma related to the nodular sclerosis.
Owner:THE THIRD MEDICAL CENT OF THE CHINESE PEOPLES LIBERATION ARMY GENERAL HOSPITAL

Renal blood vessel holder convenient to adjust

The invention discloses a kidney blood vessel clamp holder convenient to adjust, and belongs to the technical field of medical instruments, the kidney blood vessel clamp holder comprises a clamp holder body, extension arms are arranged on the clamp holder body, extension blocks are arranged on the opposite faces of the extension arms, and first connecting blocks and second connecting blocks are further arranged on the extension arms; the first connecting block and the second connecting block are hollow, and a first connecting hose is fixedly arranged between the first connecting block and the second connecting block; according to the kidney blood vessel clamping device, kidney blood vessels are clamped through the clamping device body and the extending block arranged on the clamping device body, the clamping blocks movably arranged on the extending block and the clamping device body rotationally arranged on the extending block, and the kidney blood vessels with different thicknesses can be clamped only by inflating the mounting block; air enters the fixing block through the first connecting hose and the second connecting hose, the clamping block is pushed to move, then the position of the clamping block is adjusted, limiting is achieved by closing the plug and completing sealing, then clamping operation is conducted, and convenience and rapidness are achieved.
Owner:AFFILIATED HOSPITAL OF JIANGNAN UNIV

Application of artemisinin compounds in the preparation of drugs for treating renal angiomyolipoma associated with tuberous sclerosis

The present invention belongs to the field of biomedicine technology and specifically relates to the use of artemisinin compounds in the preparation of drugs for treating tuberous sclerosis complex-associated renal angiomyolipoma. The artemisinin compounds can inhibit the growth of tuberous sclerosis complex-associated renal angiomyolipoma cells and have therapeutic efficacy in treating tuberous sclerosis complex-associated renal angiomyolipoma. Furthermore, artemisinin compounds are relatively abundant in source and relatively low in cost. Artemisinin compounds can be used to prepare drugs for treating tuberous sclerosis complex-associated renal angiomyolipoma, providing a new potential drug for the treatment of tuberous sclerosis complex-associated renal angiomyolipoma.
Owner:EXPERIMENTAL RES CENT CHINA ACAD OF CHINESE MEDICAL SCI +1

Methods for treating renal disease

Disclosed herein is a method for treating renal disease in a subject that involves treating the subject with an effective amount of a compound of the formula (I). The disclosed method can in some embodiments, be used to treat any renal disease involving mitochondrial dysfunction. For example, in some embodiments, the renal disease involves acute kidney injury. As another example, in some embodiments, the renal disease involves diabetic kidney disease. In some embodiments, the renal disease is a glomerular disease (e.g. focal segmental glomerular sclerosis). In some embodiments, the renal disease is a renal vascular disease.
Owner:THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIV OF ARIZONA

Application of cinobufotalin in preparation of medicine for resisting renal vascular smooth muscle lipoma related to nodular sclerosis

The invention belongs to the technical field of biological medicines, and particularly relates to application of cinobufotalin in preparation of a medicine for resisting renal vascular smooth muscle lipoma related to nodular sclerosis. The cinobufotalin can be used for directly inhibiting the growth of renal vascular smooth muscle lipoma cells related to the nodular sclerosis and improving the protein expression level of an apoptosis marker of the renal vascular smooth muscle lipoma cells related to the nodular sclerosis, and the cinobufotalin can be used for preparing the medicine for resisting the renal vascular smooth muscle lipoma cells related to the nodular sclerosis. Meanwhile, cinobufotalin is low in cost, and a novel, effective and low-cost potential medicine is provided for treatment of renal vascular smooth muscle lipoma related to nodular sclerosis.
Owner:EXPERIMENTAL RES CENT CHINA ACAD OF CHINESE MEDICAL SCI +1

Application of artemisinin compound in preparation of medicine for resisting renal vascular smooth muscle lipoma related to nodular sclerosis

The invention belongs to the technical field of biological medicines, and particularly relates to application of artemisinin compounds in preparation of medicines for resisting renal vascular smooth muscle lipoma related to nodular sclerosis. The artemisinin compound can inhibit the growth of renal vascular smooth muscle lipoma cells related to nodular sclerosis, has the efficacy of treating renal vascular smooth muscle lipoma related to nodular sclerosis, and meanwhile, the artemisinin compound is relatively rich in source, relatively low in cost and suitable for industrial production. The artemisinin compound can be used for preparing the medicine for treating the renal vascular smooth muscle lipoma related to the nodular sclerosis, and a new potential medicine is provided for treating the renal vascular smooth muscle lipoma related to the nodular sclerosis.
Owner:EXPERIMENTAL RES CENT CHINA ACAD OF CHINESE MEDICAL SCI +1

Systems and methods for assessing the efficacy of neuromodulation therapy

Systems and methods for performing and assessing neuromodulation therapy are disclosed herein. One method for assessing the efficacy of neuromodulation therapy includes positioning a neuromodulation catheter at a target site within a renal blood vessel of a human patient and delivering neuromodulation energy at the target site with the neuromodulation catheter. The method can further include obtaining a measurement related to a dimension of the renal blood vessel via a sensing element of the neuromodulation catheter. The measurement can be compared to a baseline measurement related to the dimension of the renal blood vessel to assess the efficacy of the neuromodulation therapy. In some embodiments, the baseline measurement is obtained via the sensing element of the neuromodulation catheter prior to delivering the neuromodulation energy.
Owner:MEDTRONIC IRELAND MFG UNLIMITED CO

Controlled flushing for neuromodulation systems and associated methods

ActiveCN111867507BCatheterHuman patient
Disclosed herein are neuromodulation catheter systems with controlled irrigation capabilities and methods for using such systems. One such method includes, for example, positioning an irrigated neuromodulation catheter at a treatment site within a renal vessel of a human patient, delivering neuromodulation energy at the treatment site, and delivering an irrigation fluid having a property coordinated with the delivered energy to the treatment site. As power is increased, the property may be adjusted to maintain the energy delivery element and / or tissue of the vessel at a constant temperature. The method may further include monitoring at least one parameter of the tissue and / or energy delivery element, and adjusting a property of the neuromodulation energy and / or irrigation fluid if the at least one parameter falls outside a therapeutic range of values.
Owner:MEDTRONIC ARDIAN LUXEMBOURG SARL